INTERACT2 was an open , blinded endpoint , randomized controlled trial in 2,839 patients with ICH within 6 hours of onset and elevated systolic BP ( SBP ) ( 150-220 mm Hg ) who were allocated to receive intensive ( target SBP < 140 mm Hg within 1 hour , with lower limit of 130 mm Hg for treatment cessation ) or guideline-recommended ( target SBP < 180 mm Hg ) BP-lowering treatment .